Upload Image (Max 20MB per Image)
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period ...
Tags: BIND Therapeutics, Kinase Inhibitor Nanomedicine